M1 Kliniken AG publishes annual report for 2025: strong growth in EBIT (+29%) and earnings per share (+40%)

M1 Kliniken AG / DE000A0STSQ8

M1 Kliniken AG / Key word(s): Annual Report/Annual Results


20.05.2026 / 08:30 CET/CEST
The issuer is solely responsible for the content of this announcement.

---

Berlin, 20 May 2026 – M1 Kliniken AG (ISIN: DE000A0STSQ8) today published its annual report for the 2025 financial year. The Group closed the financial year with a further increase in both revenue and earnings and continued its profitable growth trajectory. The development was driven in particular by efficiency gains in operational processes and the targeted expansion of medical capacities, both of which contributed to the improvement in the earnings position. Group key figures at a glance Group revenue: +7.4% to EUR 364.3 million (FY 2024: EUR 339.2 million) EBITDA: +23.6% to EUR 39.4 million (FY 2024: EUR 31.9 million) EBIT: +29.2% to EUR 34.6 million (FY 2024: EUR 26.8 million) EBIT margin: 9.5% (FY 2024: 7.9%) EBT: +29.5% to EUR 34.1 million (FY 2024: EUR 26.3 million) Earnings per share: EUR 1.19 (FY 2024: EUR 0.85) Beauty segment exceeds the EUR 100 million revenue mark for the first time Revenue: +11.2% to EUR 102.0 million (FY 2024: EUR 91.7 million) EBIT: +41.5% to EUR 28.3 million (FY 2024: EUR 20.0 million) EBIT margin: 27.8% (FY 2024: 21.8%) Trading segment with stable revenue growth Revenue: +6.0% to EUR 262.3 million (FY 2024: EUR 247.4 million) EBIT: -7.5% to EUR 6.2 million (FY 2024: EUR 6.7 million) Sale of HAEMATO Pharm GmbH successfully completed The sale of HAEMATO Pharm GmbH by its majority-owned subsidiary HAEMATO AG (85%) to the PHOENIX group was successfully completed as of the close of 31 January 2026. Following the fulfilment of all closing conditions, the transaction is legally effective; HAEMATO Pharm GmbH will be deconsolidated from HAEMATO AG and M1 Kliniken AG with effect from 1 February 2026. With this step, M1 Kliniken AG further sharpens its strategic profile and strengthens its position as the world's leading vertically integrated pure-play provider of medical aesthetics. Outlook M1 Kliniken AG will continue to pursue its profitable growth trajectory through the expansion of national and international clinics. For the Beauty segment, the company is targeting revenue of EUR 200 to 300 million by 2029, at a sustainable EBIT margin of at least 20%. The overarching objective remains to establish M1 Med Beauty as the world's leading brand for aesthetic medicine. About M1 Kliniken AG M1 Kliniken AG is the leading fully integrated provider of medical aesthetic services in Europe and Australia. With a clear strategic focus, high standardisation, and consistent scalability, the Group currently operates 59 clinics in ten countries under the M1 Med Beauty brand. All treatments are performed exclusively by qualified physicians and adhere to uniform, high medical standards, while being offered at market-leading prices. Since late 2018, M1 has systematically driven its international expansion, which forms the basis for scalable future growth and the further development of its global market position. With the M1 Schlossklinik in Berlin, the Group operates one of Europe’s largest and most modern clinics for plastic and aesthetic surgery, featuring four operating theatres and 35 beds.   Contact:
M1 Kliniken AG
Grünauer Straße 5
12557 Berlin
T: [phone]
M: [e-mail]

---

20.05.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News

---

Language:	English
Company:	M1 Kliniken AG
	Grünauer Straße 5
	12557 Berlin
	Germany
Phone:	[phone]
Fax:	[phone]
E-mail:	[e-mail]
Internet:	https://www.m1-kliniken.de
ISIN:	DE000A0STSQ8
WKN:	A0STSQ
Listed:	Regulated Unofficial Market in Dusseldorf, Frankfurt (Basic Board), Hamburg, Hanover, Munich, Stuttgart, Tradegate BSX
EQS News ID:	2330252

End of News	EQS News Service

---

2330252  20.05.2026 CET/CEST